0000885590-12-000006.txt : 20120124
0000885590-12-000006.hdr.sgml : 20120124
20120124170546
ACCESSION NUMBER: 0000885590-12-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120120
FILED AS OF DATE: 20120124
DATE AS OF CHANGE: 20120124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stolz Brian M.
CENTRAL INDEX KEY: 0001524803
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14956
FILM NUMBER: 12542529
MAIL ADDRESS:
STREET 1: VALEANT PHARMACEUTICALS INTERNATIONAL,IN
STREET 2: 7150 MISSISSAUGA ROAD
CITY: MISSISSAUGA
STATE: A6
ZIP: L5N 8M5
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7150 MISSISSAUGA ROAD
STREET 2: MISSISSAUGA
CITY: ONTARIO
STATE: A6
ZIP: 00000
BUSINESS PHONE: 905 286-3000
MAIL ADDRESS:
STREET 1: 7150 MISSISSAUGA ROAD
STREET 2: MISSISSAUGA
CITY: ONTARIO
STATE: A6
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0304
4
2012-01-20
0
0000885590
Valeant Pharmaceuticals International, Inc.
VRX
0001524803
Stolz Brian M.
VALEANT PHARMACEUTICALS INTERNATIONAL,IN
7150 MISSISSAUGA ROAD
MISSISSAUGA
A6
L5N8M5
ONTARIO, CANADA
0
1
0
0
EVP, Administration and CHCO
Common Stock, no par value
2012-01-20
4
A
0
2400
0
A
15260
D
Represents Restricted Share Units received under an employee Share Matching Program ("Matching RSUs") in connection with the officer's purchase of Company common stock. Each Matching RSU represents a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.
1/3 of the Matching RSUs will vest each on the first, second and third anniversary of the date of grant subject to contingent employment and retention of the corresponding purchased shares.
This number includes common shares purchased by the officer as well as other outstanding equity awards that were previously reported in Table 1.
by: Nicholas Zanoni for Brian Stolz
2012-01-24